Clinical Trial

Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 1, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma. Up to 20 subjects will be enrolled and randomized 1:1 to 1 of 2 cohorts, as outlined below. The initial 3 subjects will be sequentially enrolled in a staggered fashion, with a 7 day interval between each subject to enable the capture and monitoring of any acute and subacute toxicities.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2022-11-09; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2024-05-28
Trial Details
NCT Number NCT05618925
Lead Sponsor ImmunityBio, Inc.
Conditions Non Hodgkin's Lymphoma Refractory/Relapsed
Enrollment 20 participants
Start Date 2025-08-22
Primary Completion 2026-05-15 (estimated)
Study Completion 2027-03-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-01